(Q43963823)

English

The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model

scientific article published in March 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 November 2017

The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model (English)

1 reference

Europe PubMed Central

28 November 2017

Hans-Willi Krell

11

object named as

Hans-Willi Krell

0 references

author name string

Michael Lein

1

1 reference

Europe PubMed Central

28 November 2017

Klaus Jung

2

1 reference

Europe PubMed Central

28 November 2017

Bernhard Ortel

3

1 reference

Europe PubMed Central

28 November 2017

Carsten Stephan

4

1 reference

Europe PubMed Central

28 November 2017

Winfried Rothaug

5

1 reference

Europe PubMed Central

28 November 2017

Rolf Juchem

6

1 reference

Europe PubMed Central

28 November 2017

Manfred Johannsen

7

1 reference

Europe PubMed Central

28 November 2017

Serdar Deger

8

1 reference

Europe PubMed Central

28 November 2017

Dietmar Schnorr

9

1 reference

Europe PubMed Central

28 November 2017

Stefan Loening

10

1 reference

Europe PubMed Central

28 November 2017

Hans-Willi Krell

11

1 reference

Europe PubMed Central

28 November 2017

language of work or name

0 references

publication date

1 March 2002

1 reference

Europe PubMed Central

28 November 2017

1 reference

Europe PubMed Central

28 November 2017

21

1 reference

Europe PubMed Central

28 November 2017

13

1 reference

Europe PubMed Central

28 November 2017

2089-2096

1 reference

Europe PubMed Central

28 November 2017

https://scigraph.springernature.com/pub.10.1038/sj.onc.1205267

0 references

Matrix metalloproteinase inhibition: a review of anti-tumour activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Activity of type IV collagenases in benign and malignant breast disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Development of matrix metalloproteinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

New drugs on the horizon: matrix metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

21 January 2018

Workgroup I: rodent models of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

7 January 2021

based on heuristic

inferred from DOI database lookup

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

7 January 2021

based on heuristic

inferred from DOI database lookup

In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1205267

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.ONC.1205267

1 reference

Europe PubMed Central

28 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43963823&oldid=2105074841"